Disease · MONDO_0009348

classic Hodgkin lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. classic Hodgkin lymphoma. Diseases, record MONDO_0009348. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009348

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: classic Hodgkin lymphoma; Open Targets
Open Targets ID: MONDO_0009348; Open Targets
Other names: classic Hodgkin disease, classical Hodgkin lymphoma, classical Hodgkin's lymphoma; Open Targets
NCI Thesaurus: C7164; NCI Thesaurus
Orphanet: ORPHA:391; Orphanet
Highest stage of its drugs: Approval, for 1 of its 88 drugs, from DailyMed; Open Targets

Drugs88

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	DailyMed	33	32	32	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	36	36	36	Drugs and targets
BRENTUXIMAB VEDOTIN	CHEMBL1742994	Antibody drug conjugate	Phase 3	ClinicalTrials.gov	34	34	34	Drugs and targets
DACARBAZINE	CHEMBL476	Small molecule	Phase 3	ClinicalTrials.gov	31	31	31	Drugs and targets
VINBLASTINE	CHEMBL159	Small molecule	Phase 3	ClinicalTrials.gov	24	24	24	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	21	21	20	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	18	18	18	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	11	11	10	Drugs and targets
BLEOMYCIN	CHEMBL6067492		Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
BENDAMUSTINE	CHEMBL487253	Small molecule	Phase 3	ClinicalTrials.gov	9	9	8	Drugs and targets

1 to 10 of 88

See all 88 drugs

Targets116

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	11	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
TUBA1A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 116

See all 116 targets

Trials143

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01712490	A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma	Phase 3	1,334	2018-11-27	Hodgkin Lymphoma	BLEOMYCIN, BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE	Its record names the disease	ClinicalTrials.gov
NCT03907488	Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma	Phase 3	994	2025-06-12	Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma	BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN HYDROCHLORIDE, NIVOLUMAB, VINBLASTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT02166463	Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma	Phase 3	600	2023-05-31	Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma	BLEOMYCIN SULFATE, BRENTUXIMAB VEDOTIN, CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, METHYLPREDNISOLONE, PREDNISONE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT02181738	Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)	Phase 2	294	2018-12-11	Hodgkin Disease	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT03646123	Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma	Phase 2	255	2023-12-21	Hodgkin Lymphoma	BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN, NIVOLUMAB, VINBLASTINE	Its record names the disease	ClinicalTrials.gov
NCT02453594	Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)	Phase 2	211	2024-10-29	Hodgkin Lymphoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05008224	Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)	Phase 2	146	2024-10-16	Classical Hodgkin Lymphoma	BLEOMYCIN, CYCLOPHOSPHAMIDE, DACARBAZINE, DOXORUBICIN, ETOPOSIDE, PEMBROLIZUMAB, PREDNISONE, PROCARBAZINE, VINBLASTINE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00742027	Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma	Phase 2	129	2021-06-03	Classical Hodgkin's Lymphoma	PANOBINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT03114683	Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma	Phase 2	96	2020-12-07	Relapsed/Refractory Classical Hodgkin's Lymphoma	SINTILIMAB	Its record names the disease	ClinicalTrials.gov
NCT03446040	An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread	Phase 1/2	92	2025-09-18	Advanced Cancer	BMS-986258, HYALURONIDASE (HUMAN RECOMBINANT), NIVOLUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 143

See all 143 trials

Comparisons in its trials33

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
A+AVD vs ABVD: Number of Participants With Abnormal Clinical Laboratory Values	662 of 662	658 of 659	1,321	NCT01712490	Trial comparisons
A+AVD vs ABVD: deaths from any cause	9 of 662	13 of 659	1,321	NCT01712490	Trial comparisons
A+AVD vs ABVD: serious adverse events	284 of 662	178 of 659	1,321	NCT01712490	Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Overall Survival	7 of 487	14 of 483	970	NCT03907488	Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Event-free Survival (EFS)	52 of 487	91 of 483	970	NCT03907488	Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Progression Free Survival (PFS)	41 of 487	81 of 483	970	NCT03907488	Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): deaths from any cause	7 of 487	14 of 483	970	NCT03907488	Trial comparisons
Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): serious adverse events	140 of 481	18 of 476	957	NCT03907488	Trial comparisons
Arm I (ABVE-PC) vs ARM II (Bv-AVEPC): deaths from any cause	4 of 289	2 of 298	587	NCT02166463	Trial comparisons
Arm I (ABVE-PC) vs ARM II (Bv-AVEPC): serious adverse events	11 of 287	66 of 295	582	NCT02166463	Trial comparisons

1 to 10 of 33

See all 33 comparisons in its trials

Papers from its trials98

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37319435	RESULT	1	PubMed
33062947	RESULT	1	PubMed
32786092	RESULT	1	PubMed
32352505	RESULT	2	PubMed
31520078	RESULT	1	PubMed
31112476	RESULT	2	PubMed
28434018	RESULT	1	PubMed
24089446	RESULT	1	PubMed
22371887	RESULT	1	PubMed
42826707	DERIVED	1	PubMed

1 to 10 of 98

See all 98 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0009348

GET https://conductscience.org/api/diseases/v1/MONDO_0009348/drugs?page=2

API reference For AI assistants